在儿童生长激素刺激测试期间,Ondansetron定时对症状负担和诊断性能的影响
概括
丹不影响儿童生长激素 (GH) 测试的准确性,并可能减少恶心. 身体质量指数 (BMI) 标准偏差得分 (SDS) 对于解释GH测试结果很重要.
科学领域:
- 儿科内分泌学 儿科内分泌学
- 临床药理学 临床药理学
背景情况:
- 使用乐沃多巴/卡比多巴进行生长激素 (GH) 刺激测试可能会引起恶心和吐.
- 丹塞经常用于症状管理,但其对GH测试准确性的影响尚未得到充分证实.
研究的目的:
- 评估丹塞定时对儿童GH刺激测试准确性的影响.
- 为了确定影响GH测试反应和GH缺乏症分类的因素.
主要方法:
- 对129名儿童 (2-16岁) 进行氨酸-莱沃多巴/卡比多巴GH刺激测试的回顾性分析.
- 丹塞的服用时间分类:没有,早 (0-30分钟),或晚 (31-120分钟).
- 多变量回归模型评估了Ondansetron时间,临床因素和GH测试结果 (GH峰值,GH缺乏) 之间的关联.
主要成果:
- 丹的时间没有显著影响GH峰值度或GH缺乏症分类.
- 恶心和吐在晚期的丹塞特朗组 (51%) 比较早 (38%) 或没有 (25%) 更为普遍.
- 较高的身体质量指数标准偏差分数 (BMI SDS) 与较低的峰值GH相关,并增加了GH缺乏的几率.
结论:
- 丹塞特朗的使用不会改变GH刺激测试的准确性,并且可以有效地管理相关症状.
- BMI SDS是GH测试反应的独立预测指标,对于准确解释结果至关重要.
更多相关视频
07:20Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
Published on: August 9, 2024
1.8K
05:48The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
Published on: June 12, 2020
6.3K
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
602
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
602
Therapeutic Drug Monitoring: Affecting Factors
201
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
201
Drug Dosing: Infants and Children
255
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
255
Pharmacokinetics in Pediatric Patients: Drug Metabolism
193
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
193
Drug Dosing: Obese Patients
225
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
225
Pharmacokinetics in Pediatric Patients: Drug Excretion
212
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
212
